undamentalytics Newsletter
Sign in

Zymeworks Inc. balance sheet

At the end of fiscal 2025, Zymeworks Inc. had total assets of $347m, total liabilities of $78.0m and shareholders' equity of $269m. It held $41.2m in cash against $0 of debt: net cash of $41.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2422024011586641179
Receivables—1633195656
Total current assets—288545413300249298
Goodwill—121212121212
Total assets—389649581463347397
Deferred revenue (current)—02426216
Total current liabilities—729656884247
Total debt0000000
Total liabilities—14015611612478317
Shareholders' equity41024949346533926980
Net debt (negative = net cash)−242−202−401−158−66−41−179
Shares outstanding—47m63m70m69m75m71m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NBTX vs ZYMEFHTX vs ZYMECUE vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Zymeworks Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zymeworks Inc.